N-Boc-O-Benzyl-D-serine

We are N-Boc-O-Benzyl-D-serine CAS:47173-80-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N-Boc-O-Benzyl-D-serine
CAS.NO: 47173-80-8
Molecular Formula: C15H21NO5
Molecular Weight: 295.33100

Synonyms:
tert-butyloxycarbonyl-O-benzyl-D-serine
BOC-L-SER(BZL)-OH
Boc-D-Ser(Bzl)-OH
O-Benzyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-serine
BOC-SER(BZL)-OH
N-t-BOC-O-benzyl-D-serine
N-BOC-O-Benzyl-D-serine
tert-butoxycarbonyl-O-benzyl-D-serine
BOC-SER(BZL)
(2R)-3-Benzyloxy-2-tert-butoxycarbonylaminopropionic acid
O-Benzyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-D-serine
TBOC-L-SERINE (BZL)
O-Benzyl-N-(tert-butoxycarbonyl)-L-serine
BOC-L-SER(BZL)
D-Serine, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-
N-(t-Butoxycarbonyl)-O-benzyl-D-serine

Physical and Chemical Properties:
Density: 1.174g / cm3
Boiling point: 456.2ºC at 760mmHg
Melting point: 58-60 ° C (lit.)
Flash point: 229.7ºC
Refractive index: 1.523

Specification:
Appearance:  White crystalline powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at2-8ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Related News: Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.N6-Benzoyladenosine CAS:4546-55-8 Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December.Thioacetic acid The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).1-Bromo-2-(1-Methylethyl)Benzene The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.